Ovata Capital Management’s Humacyte HUMA Stock Holding History

Ovata Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-800	Closed	-$6K	–	89
2022 Q1	$6K	Buy	+800	New	+$4.66K	﹤0.01%	132

Other funds holding HUMA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Ovata Capital Management's HUMA Position: Q2 2022 in Review

Ovata Capital Management sold out of Humacyte (HUMA) in Q2 2022, closing a stake of 800 shares — an estimated $6K sold.

Ovata Capital Management first reported a position in HUMA in Q1 2022 and held it in 1 quarter. The position peaked at $6K in Q1 2022. 78 funds tracked by Wall St. Rank hold HUMA as of Q2 2022.

Ovata Capital Management reported no remaining Humacyte position as of Q2 2022 after selling out during the quarter.
Ovata Capital Management sold 800 Humacyte shares in Q2 2022, an estimated $6K.
Ovata Capital Management first reported a position in Humacyte in Q1 2022 and held it in 1 quarter.
Ovata Capital Management's Humacyte position peaked at $6K in Q1 2022.
78 funds tracked by Wall St. Rank held Humacyte as of Q2 2022.

Based on Ovata Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.